Colchicine in the Management of Acute and Chronic Coronary Artery Disease

[1] Benjamin EJ(2019)Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association Circulation. 139 e56-e528

[2] Muntner P(2015)Global and regional patterns in cardiovascular mortality from 1990 to 2013 Circulation. 132 1667-1678

[3] Alonso A(2015)Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective Eur Heart J 36 1163-1170

[4] Bittencourt MS(2016)2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines J Am Coll Cardiol 68 1082-1115

[5] Callaway CW(2016)Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin Eur Heart J 37 1720-1722

[6] Carson AP(2017)Failure to launch: targeting inflammation in acute coronary syndromes JACC Basic Transl Sci 2 484-497

[7] Chamberlain AM(2009)Leducq Transatlantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice J Am Coll Cardiol 54 2129-2138

[8] Chang AR(2020)From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 141 787-789

[9] Cheng S(1954)History of the use of colchicum and related medicaments in gout; with suggestions for further research Ann Rheum Dis 13 190-200

[10] Das SR(2004)Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature. 428 198-202

[1] Benjamin EJ(2019)Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association Circulation. 139 e56-e528

[2] Muntner P(2015)Global and regional patterns in cardiovascular mortality from 1990 to 2013 Circulation. 132 1667-1678

[3] Alonso A(2015)Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective Eur Heart J 36 1163-1170

[4] Bittencourt MS(2016)2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines J Am Coll Cardiol 68 1082-1115

[5] Callaway CW(2016)Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin Eur Heart J 37 1720-1722

[6] Carson AP(2017)Failure to launch: targeting inflammation in acute coronary syndromes JACC Basic Transl Sci 2 484-497

[7] Chamberlain AM(2009)Leducq Transatlantic Network on A. Inflammation in atherosclerosis: from pathophysiology to practice J Am Coll Cardiol 54 2129-2138

[8] Chang AR(2020)From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 141 787-789

[9] Cheng S(1954)History of the use of colchicum and related medicaments in gout; with suggestions for further research Ann Rheum Dis 13 190-200

[10] Das SR(2004)Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature. 428 198-202